[Managing the discontinuation of GLP-1 agonists : how to insure a smooth transition].

Abstract

Glucagon-like peptide-1 receptor agonists have revolutionized the management of obesity. However, when they are discontinued, often due to reimbursement limitations, there is a high risk of weight regain. This is linked to complex biological mechanisms, including hormonal disruption, a drop in basal metabolism, and dysregulation of central reward circuits. Lasting weight loss is best achieved through a gradual transition, accompanied by professional and interdisciplinary follow-up that includes nutritional, psychological, and behavioral interventions, as well as adapted physical activity. A comprehensive approach based on therapeutic patient education is essential for maintaining long-term therapeutic benefits and preventing rebound effects.